Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Concentration-controlled zidovudine therapy

C V Fletcher1, E P Acosta, K Henry

  • 1Division of Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, USA. fletc001@tc.umn.edu

Clinical Pharmacology and Therapeutics
|October 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

The Journal of antimicrobial chemotherapy·2020
Same author

Screening for Epstein-Barr virus (EBV) infection status in university freshmen: acceptability of a gingival swab method.

Epidemiology and infection·2019
Same author

The impact of recipient BKV shedding before transplant on BKV viruria, DNAemia, and nephropathy post-transplant: A prospective study.

Pediatric transplantation·2017
Same author

Pharmacokinetics of tenofovir during pregnancy and postpartum.

HIV medicine·2015
Same author

Helicase-primase as a target of new therapies for herpes simplex virus infections.

Clinical pharmacology and therapeutics·2015

A novel concentration-controlled zidovudine regimen improved anti-human immunodeficiency virus (HIV) response by increasing systemic and intracellular drug levels compared to standard dosing. This approach reduced patient variability and led to a significant increase in CD4 cell counts.

Area of Science:

  • Pharmacology
  • Immunology
  • Virology

Background:

  • Patient response to antiretroviral therapy (ART) varies due to pharmacologic, immunologic, and virologic factors.
  • Standard fixed doses of nucleoside anti-HIV drugs are currently used, but intracellular anabolite levels can vary.
  • This variability may stem from differences in drug metabolism at both systemic and cellular levels.

Purpose of the Study:

  • To evaluate if a concentration-controlled zidovudine regimen enhances anti-HIV response compared to standard fixed-dose therapy.
  • To investigate the impact of pharmacologic variability on treatment outcomes.

Main Methods:

  • A randomized, crossover study involving 20 individuals with HIV infection.
  • Participants received either a concentration-controlled zidovudine regimen targeting 0.7 mumol/L plasma concentration or a standard 500 mg/day dose.

Related Experiment Videos

  • The study lasted 24 weeks, with assessments of plasma and intracellular drug concentrations, safety, and CD4 cell counts.

    • Main Results:

    • The concentration-controlled regimen resulted in higher average plasma zidovudine concentrations (0.76 mumol/L vs. 0.62 mumol/L) with less interpatient variability.
    • Intracellular zidovudine triphosphate levels were significantly higher with the concentration-controlled regimen (160 fmol/10(6) PBMCs vs. 92 fmol/10(6) PBMCs).
    • Patients on the concentration-controlled regimen showed a 22% increase in CD4 cells from baseline, while the standard dose group had a 7% decrease.

    Conclusions:

    • Pharmacologic variability significantly influences antiretroviral treatment response.
    • Concentration-controlled dosing of zidovudine can optimize therapeutic benefits by reducing interpatient variability.
    • These findings support a framework for characterizing pharmacologic determinants to improve HIV treatment outcomes.